📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Rossari Biotech Reports Record Q4 FY26 Revenue of ₹685 Cr, PAT Up 34% YoY
Rossari Biotech achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, driven by double-digit growth across all business segments including HPPC, TSC, and AHN. For the full year FY26, revenue grew 15.2% to ₹2,396.4 crore, though EBITDA margins slightly compressed to 11.9% from 12.7% due to raw material cost volatility. The company successfully commissioned an additional 15,000 MTPA ethoxylation capacity at Dahej, bringing the total to 66,000 MTPA. A dividend of ₹0.50 per share has been recommended for the fiscal year.
Key Highlights
Q4 FY26 Revenue grew 18.2% YoY to ₹684.9 crore, the highest quarterly performance to date.
Quarterly Net Profit (PAT) surged 33.7% YoY to ₹46.0 crore in Q4 FY26.
Full-year FY26 Revenue reached ₹2,396.4 crore with a consolidated PAT of ₹149.2 crore.
Commissioned 15,000 MTPA ethoxylation capacity at Dahej facility on March 31, 2026.
Net Debt to Equity remains healthy at 0.21x despite ongoing capital expenditure.
💼 Action for Investors
Investors should focus on the company's ability to pass on raw material costs to recover margins and the scaling of the newly added ethoxylation capacity. The narrowing losses in the B2C segment and strong core B2B growth suggest a positive outlook for the specialty chemicals platform.
Loading analysis...
Rossari Biotech Q4 FY26 PAT Jumps 34% YoY to ₹46 Cr; Revenue Up 18% to ₹684.9 Cr
Rossari Biotech reported its highest-ever quarterly revenue of ₹684.9 crore for Q4 FY26, marking an 18% YoY growth driven by strong performance across all business segments. While EBITDA grew 11% to ₹77.3 crore, EBITDA margins contracted slightly to 11.3% from 12.0% due to raw material cost inflation and pricing lags. Net profit (PAT) saw a significant surge of 34% YoY to ₹46.0 crore. The company also successfully commissioned additional ethoxylation capacity at Dahej, bringing the total to 66,000 MTPA, and recommended a dividend of ₹0.50 per share.
Key Highlights
Q4 FY26 Revenue from operations grew 18% YoY to ₹684.9 crore, the highest quarterly revenue ever.
Consolidated PAT for Q4 FY26 increased by 34% YoY to ₹46.0 crore from ₹34.4 crore.
EBITDA margins compressed to 11.3% in Q4 FY26 compared to 12.0% in the previous year's quarter.
Unitop commissioned 15,000 MTPA additional ethoxylation capacity at Dahej, reaching a total of 66,000 MTPA.
The Board recommended a dividend of ₹0.50 per share for the financial year 2025-26.
💼 Action for Investors
Investors should monitor the company's ability to pass on raw material costs to recover margins in the coming quarters. The strong top-line growth and capacity expansion indicate a robust demand outlook, supporting a positive long-term view.
Loading analysis...
Rossari Biotech: Re. 0.50 Dividend, ESOP Allotment, and Capacity Expansion Update
Rossari Biotech's board has approved a final dividend of Re. 0.50 per share (25%) for the financial year ended March 31, 2026. The company also allotted 8,250 equity shares under its ESOP 2019 plan at an exercise price of Rs. 425 per share. Crucially, the company is rescheduling its previously announced capacity expansion project to a phased implementation over the next two years. To bolster innovation, a new R&D facility has been established in Navi Mumbai, and Mr. Udeypaul Singh Gill has been appointed as an Independent Director.
Key Highlights
Recommended a final dividend of Re. 0.50 per equity share (25% of face value Rs. 2) for FY 2025-26.
Allotted 8,250 equity shares under ESOP 2019, increasing paid-up capital to Rs. 11.08 crore.
Rescheduled the capacity expansion project to a phased rollout over the next 24 months due to market conditions.
Established a new R&D facility in Navi Mumbai and relocated existing IIT Bombay operations there.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
💼 Action for Investors
Investors should monitor the impact of the delayed capacity expansion on long-term growth targets while noting the company's continued focus on R&D. The dividend is modest, so the focus remains on the upcoming full audited financial performance details.
Loading analysis...
Rossari Biotech Recommends Rs 0.50 Dividend and Reschedules Capacity Expansion Project
Rossari Biotech has recommended a final dividend of Rs. 0.50 per share (25% of face value) for the financial year ended March 31, 2026. The company is re-evaluating its previously announced capacity expansion project, which will now be implemented in a phased manner over the next two years instead of the original timeline. To bolster innovation, the company has established a new R&D facility in Navi Mumbai, shifting operations from its existing IIT Bombay site. Additionally, the board approved the appointment of industry veteran Mr. Udeypaul Singh Gill as an Independent Director.
Key Highlights
Recommended final dividend of Rs. 0.50 per share (25%) on equity shares of face value Rs. 2 each.
Rescheduled capacity expansion project to be implemented in a phased manner over the next 24 months.
Established a new Research and Development facility at Navi Mumbai to enhance innovation and product development.
Allotted 8,250 equity shares under the Rossari Employee Stock Option Plan - 2019 at an exercise price of Rs. 425.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
💼 Action for Investors
Investors should monitor the impact of the rescheduled capacity expansion on long-term growth targets while noting the company's increased focus on R&D. The dividend yield remains modest, so the primary focus should be on the execution of the phased investment plan.
Loading analysis...
Rossari Biotech Declares Rs 0.50 Dividend and Reschedules Capacity Expansion Project
Rossari Biotech has approved its audited financial results for FY26 and recommended a final dividend of Rs. 0.50 per share (25% of face value). The company is rescheduling its major capacity expansion project to a phased implementation over the next two years to align with market conditions. In a move to boost innovation, a new R&D facility has been established in Navi Mumbai, replacing the existing IIT Bombay unit. Additionally, the board appointed Mr. Udeypaul Singh Gill as an Independent Director and allotted 8,250 shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of Rs. 0.50 per equity share (25%) for the financial year 2025-26.
Rescheduled the implementation of its capacity expansion project to a phased manner over the next two years.
Established a new Research and Development facility in Navi Mumbai, relocating from the IIT Bombay site.
Appointed Mr. Udeypaul Singh Gill as an Independent Director for a three-year term starting April 28, 2026.
Allotted 8,250 equity shares under the ESOP 2019 plan at an exercise price of Rs. 425 per share.
💼 Action for Investors
Investors should monitor the reasons for the expansion delay and the impact of the new R&D facility on product innovation. The dividend yield is relatively low, so focus should remain on the company's ability to execute its phased growth strategy.
Loading analysis...
Rossari Biotech Subsidiary Unitop Commissions 15,000 MTPA Capacity; Total Reaches 66,000 MTPA
Rossari Biotech's material subsidiary, Unitop Chemicals Private Limited, has successfully commissioned the final 15,000 MTPA of its planned 30,000 MTPA ethoxylation expansion at its Dahej facility. This marks the completion of a multi-year expansion project, bringing Unitop's total installed ethoxylation capacity to 66,000 MTPA effective March 31, 2026. The increased capacity is expected to drive significant volume growth and strengthen the company's market position in specialty chemicals. Investors should expect enhanced revenue contributions from this subsidiary starting from the first quarter of FY27.
Key Highlights
Successfully commissioned the remaining 15,000 MTPA ethoxylation capacity at the Dahej facility.
Completion of the total planned 30,000 MTPA expansion project first announced in October 2023.
Total installed ethoxylation capacity for subsidiary Unitop Chemicals now stands at 66,000 MTPA.
The new capacity is operational as of March 31, 2026, aligning with the start of the new fiscal year.
💼 Action for Investors
Investors should monitor the ramp-up in capacity utilization and its subsequent impact on the consolidated margins and top-line growth in upcoming quarterly results.
Loading analysis...
Rossari Biotech Infuses SAR 8 Million into Subsidiary Rossari International
Rossari Biotech Limited has announced a capital infusion of SAR 8 million into its wholly-owned subsidiary, Rossari International Limited Company. The investment involved subscribing to 8,000 shares at a face value of SAR 1,000 per share on February 18, 2026. This transaction follows previous intimations made by the company in November 2024 and October 2025. The move signifies the company's continued focus on scaling its international operations and footprint in the Middle East region.
Key Highlights
Investment of SAR 8 million (Saudi Riyal) in Rossari International Limited Company.
Acquisition of 8,000 shares at a face value of SAR 1,000 each.
The target entity is a 100% wholly-owned subsidiary of Rossari Biotech.
Follow-up to previous strategic expansion disclosures made in October 2025.
💼 Action for Investors
Investors should view this as a commitment to international growth; monitor the subsidiary's contribution to consolidated revenue in future quarters. Maintain a long-term outlook as these capital infusions are part of a planned expansion strategy.
Loading analysis...
Rossari Biotech Wins Arbitration; Sellers' Put Option Claim for Unitop Chemicals Dismissed
Rossari Biotech has received a final arbitral award regarding a dispute with the former shareholders of its subsidiary, Unitop Chemicals. The Arbitral Tribunal dismissed the sellers' claim which sought to force Rossari to purchase the third tranche of shares via a Put Option. While the company's counterclaims were also dismissed, the financial liability is restricted to a tax refund of INR 97.91 lakhs plus 12% interest. This outcome is favorable as it prevents a potentially large mandatory cash outflow for share acquisition.
Key Highlights
Arbitral Tribunal dismissed Sellers' claim to exercise a Put Option for the third tranche of Unitop Chemicals shares
Company's counterclaims were dismissed, resulting in a limited financial liability of INR 97,90,617
Rossari directed to pay the tax refund amount with 12% interest per annum
Arbitration costs are to be shared equally between Rossari and the Sellers
Management confirms the award will not have any material impact on the company's financials
💼 Action for Investors
Investors should view this as a positive resolution as it removes the legal uncertainty and potential financial burden of a forced share purchase. No immediate action is required as the financial impact is negligible relative to the company's size.
Loading analysis...
Rossari Biotech Q3 FY26 Revenue Up 13% to ₹581.7 Cr; Plans Greenfield Expansion in Saudi Arabia
Rossari Biotech reported a 13% YoY revenue growth to ₹581.7 crore in Q3 FY26, driven by strong performance in Animal Health (+39%) and Textile Specialty Chemicals (+18%). Consolidated EBITDA margins stood at 11.8%, impacted by new labor codes and capacity expansion costs, though core B2B margins remained higher at 14%. A significant strategic move includes the in-principle approval for a greenfield specialty chemicals facility in Saudi Arabia to enhance global supply chain resilience and target the MENA and European markets. Management expects capacity utilization for new facilities to reach optimal levels by 2027.
Key Highlights
Consolidated revenue grew 13% YoY to ₹581.7 crore, supported by a 26% growth in exports during 9M FY26.
Animal Health and Nutrition segment led growth with a 39% YoY increase, while Textile Specialty Chemicals grew 18%.
Consolidated EBITDA stood at ₹68.9 crore (11.8% margin), while core B2B operations delivered a 14% margin.
Board granted in-principle approval for a greenfield specialty chemicals manufacturing facility in Saudi Arabia (KSA).
Newly commissioned 15,000 MTPA Ethoxylation facility at Unitop is ramping up, with full utilization expected within 2 years.
💼 Action for Investors
Investors should monitor the execution of the Saudi Arabia expansion and the ramp-up of the Ethoxylation capacities, as these are key drivers for long-term margin improvement. The company remains a strong growth play in specialty chemicals despite near-term margin pressure from expansion and labor costs.
Loading analysis...
Rossari Biotech Q3 Revenue Rises 13% to Rs 581.7 Cr; Plans Saudi Arabia Expansion
Rossari Biotech reported a 13% YoY revenue growth in Q3 FY26, reaching Rs 581.7 crore, driven by strong performance in Animal Health and Nutrition (+39%) and Textile Specialty Chemicals (+18%). However, EBITDA margins contracted to 11.8% from 12.6% due to investments in capacity and market development, leading to a modest 3% growth in PAT to Rs 32.8 crore. A significant strategic development is the in-principle approval for a new greenfield manufacturing facility in Saudi Arabia to enhance global supply capabilities. The company maintains a positive outlook despite domestic demand softness, relying on its diversified segment mix.
Key Highlights
Consolidated Revenue grew 13% YoY to Rs 581.7 crore in Q3 FY26
EBITDA increased 6% to Rs 68.9 crore, but margins compressed by 80 bps to 11.8%
Animal Health and Nutrition (AHN) segment showed robust growth of 39% YoY
Board approved a greenfield specialty chemicals facility in Saudi Arabia (KSA)
9M FY26 PAT stands at Rs 103.2 crore, showing a marginal 1% growth YoY
💼 Action for Investors
Investors should monitor the impact of margin compression on profitability despite steady top-line growth. The Saudi expansion is a significant long-term growth driver, but execution and funding details remain key monitorables.
Loading analysis...
Rossari Biotech Q3 FY26 Revenue Up 13.5% YoY to ₹581.7 Cr; Plans Saudi Arabia Expansion
Rossari Biotech reported a steady 13.5% YoY growth in consolidated revenue to ₹581.7 crore for Q3 FY26, supported by strong performance in Animal Health and Nutrition (+39% YoY) and Textile Specialty Chemicals (+18% YoY). However, EBITDA margins contracted by 80 bps to 11.8% due to ongoing investments in capacity expansion and market-seeding initiatives. A major strategic highlight is the board's in-principle approval to establish a greenfield specialty chemicals manufacturing facility in Saudi Arabia. While domestic demand in Institutional and B2C segments remained muted, the company's export focus and diversified portfolio helped maintain growth momentum.
Key Highlights
Consolidated Revenue increased 13.5% YoY to ₹581.7 crore, while PAT grew 3.5% YoY to ₹32.8 crore.
Animal Health and Nutrition (AHN) segment recorded the highest growth at 39% YoY, reaching ₹39 crore.
EBITDA margins compressed to 11.8% from 12.6% YoY, primarily due to higher employee benefits and other expenses related to expansion.
Board granted in-principle approval for a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA) via a wholly-owned subsidiary.
Home, Personal Care and Performance Chemicals (HPPC) remains the largest segment, contributing ₹431 crore to revenue with 11% YoY growth.
💼 Action for Investors
Investors should focus on the company's transition toward international markets and the potential margin recovery as new capacities scale up. The Saudi Arabia expansion is a significant long-term catalyst for global supply chain integration.
Loading analysis...
Rossari Biotech to Expand in Saudi Arabia and Sell Mumbai Asset for Rs 25 Crore
Rossari Biotech's board has granted in-principle approval for a new greenfield specialty chemicals manufacturing facility in Saudi Arabia to enhance its global supply chain. The company is also divesting its non-operational Kanjurmarg office for Rs 25 crore to Bhagwati Grand Celebration LLP, with completion expected by March 2026. Additionally, the board approved the Q3 FY26 financial results and the closure of its Bangladesh subsidiary. These strategic moves indicate a focus on international expansion and the monetization of non-core assets.
Key Highlights
In-principle approval for a greenfield specialty chemicals plant in Saudi Arabia (KSA) via Rossari International Limited.
Sale of non-operational Kanjurmarg office premises for a consideration of Rs 25 crore.
Closure of wholly-owned subsidiary Rossari Bangladesh Limited approved by the board.
Allotment of 2,000 equity shares under ESOP 2019 at an exercise price of Rs 425 per share.
Unaudited financial results for the quarter and nine months ended December 31, 2025, approved and taken on record.
💼 Action for Investors
The KSA expansion is a significant long-term growth driver for international markets, while the Rs 25 crore asset sale provides a healthy liquidity boost from non-core assets. Investors should monitor the detailed Q3 earnings report for operational margins and growth trends.
Loading analysis...
Rossari Biotech Approves KSA Expansion, ₹25 Cr Asset Sale, and Q3 Results
Rossari Biotech's board has granted in-principle approval for a greenfield specialty chemicals facility in Saudi Arabia to enhance its global supply chain. The company is also monetizing a non-core office asset in Kanjurmarg for ₹25 crore, with completion expected by March 2026. Additionally, the board approved the Q3 FY26 financial results and the closure of its Bangladesh subsidiary. A minor ESOP allotment of 2,000 shares was also confirmed at an exercise price of ₹425 per share.
Key Highlights
In-principle approval for greenfield specialty chemical manufacturing facilities in Saudi Arabia (KSA).
Sale of Kanjurmarg office premises for ₹25 Crores to Bhagwati Grand Celebration LLP.
Closure of wholly-owned subsidiary Rossari Bangladesh Limited approved by the board.
Allotment of 2,000 equity shares under ESOP 2019, increasing paid-up capital to ₹11.07 Crore.
Approval of Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
💼 Action for Investors
Investors should view the Saudi Arabia expansion as a significant strategic move for international growth. The ₹25 crore asset monetization provides immediate liquidity that can be redeployed into core business operations.
Loading analysis...
Rossari Biotech Approves Saudi Arabia Greenfield Project & Rs 25 Cr Asset Sale
Rossari Biotech's board has granted in-principle approval for a new greenfield specialty chemicals manufacturing facility in Saudi Arabia to enhance its global supply chain and market speed. The company is also monetizing non-core assets by selling its Kanjurmarg office premises for Rs. 25 Crores, expected to be completed by March 2026. Additionally, the board approved the closure of its Bangladesh subsidiary to streamline operations and allotted 2,000 shares under its ESOP scheme. The Saudi project will be financed through a combination of equity, debt, and internal accruals.
Key Highlights
In-principle approval for a greenfield specialty chemicals facility in Saudi Arabia (KSA) via Rossari International Limited.
Sale of Kanjurmarg office premises for Rs. 25 Crores to Bhagwati Grand Celebration LLP.
Closure of wholly-owned subsidiary Rossari Bangladesh Limited approved by the board.
Allotment of 2,000 equity shares under ESOP 2019 at an exercise price of Rs. 425 per share.
Total paid-up equity share capital increased to Rs. 11,07,66,732 following the new allotment.
💼 Action for Investors
Investors should view the Saudi expansion as a positive long-term growth driver for international market penetration. The Rs 25 crore asset sale provides immediate liquidity that can be redeployed into these high-growth manufacturing projects.
Loading analysis...
Rossari Biotech Incorporates Wholly Owned Subsidiary in Singapore
Rossari Biotech Limited has announced the successful incorporation of a new wholly-owned subsidiary, Rossari (Singapore) Pte. Ltd., in the Republic of Singapore. The incorporation was finalized on December 18, 2025, following the issuance of a certificate by the Accounting and Corporate Regulatory Authority (ACRA) of Singapore. This strategic move is intended to strengthen the company's international presence and streamline global operations. The disclosure follows regulatory requirements under SEBI's Listing Obligations and Disclosure Requirements.
Key Highlights
Incorporation of Rossari (Singapore) Pte. Ltd. as a 100% wholly-owned subsidiary
Official incorporation date confirmed as December 18, 2025
Certificate of incorporation issued by ACRA, Singapore
Compliance maintained under Regulation 30 of SEBI (LODR) Regulations, 2015
💼 Action for Investors
Investors should view this as a positive step toward global expansion and monitor future updates regarding capital allocation and business operations in the Singapore market.
Loading analysis...
Rossari Biotech to Incorporate Singapore Subsidiary with $10 Million Investment
Rossari Biotech's board has approved the incorporation of a wholly owned subsidiary in Singapore, tentatively named Rossari (Singapore) Pte. Limited. The company plans an initial capital investment of up to USD 10 million, which will be deployed in multiple tranches. This strategic move is aimed at increasing the company's global footprint and facilitating international investments. The incorporation process is expected to be completed by the fourth quarter of the 2025-26 fiscal year.
Key Highlights
Approved the formation of a 100% owned subsidiary in the Republic of Singapore
Initial capital investment commitment of up to USD 10 million to be paid in tranches
The new entity will serve as a strategic vehicle for global expansion and investments
Incorporation is projected to be finalized by Q4 FY26 subject to regulatory approvals
💼 Action for Investors
Investors should monitor this development as a signal of the company's intent to scale internationally and diversify its revenue base. This expansion could lead to future M&A activities or new market entries managed through the Singapore hub.